Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery

JM. Kirkwood, MD. Vecchio, J. Weber, C. Hoeller, JJ. Grob, P. Mohr, C. Loquai, C. Dutriaux, V. Chiarion-Sileni, J. Mackiewicz, P. Rutkowski, P. Arenberger, G. Quereux, TM. Meniawy, PA. Ascierto, AM. Menzies, P. Durani, M. Lobo, F. Campigotto, B....

. 2024 ; 20 (15) : 959-968. [pub] 20240223

Language English Country England, Great Britain

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc24006490

WHAT IS THIS SUMMARY ABOUT?: In this article, we summarize results from the ongoing phase 3 CheckMate 76K clinical study published online in Nature Medicine in October 2023. The study goal was to learn whether nivolumab works as an adjuvant therapy (that is, helps to keep cancer from coming back when it is given after surgery) for stage 2 melanoma (skin cancer) that has not spread to other parts of the body. Nivolumab is an immunotherapy that activates a person's immune system so it can destroy cancer cells. In melanoma, staging describes the severity of the cancer. Melanoma staging ranges from 0 (very thin and confined to the upper layer of the skin) to 4 (spread to distant parts of the body), with earlier stages removed by surgery. The people in this study had stage 2 melanoma that had not spread to the lymph nodes or other organs in the body. HOW WAS THE STUDY DESIGNED?: People 12 years and older with stage 2 melanoma that had not spread and had been removed by surgery were included in CheckMate 76K. People were randomly assigned to receive either nivolumab (526 patients) or placebo (264 patients). A placebo resembles the test medicine but does not contain any active medicines. The researchers assessed whether people who received nivolumab lived longer without their cancer returning and/or spreading to other parts of their bodies (compared with placebo) and if nivolumab was well tolerated. WHAT WERE THE RESULTS?: Researchers found that people who received nivolumab were 58% less likely to have their cancer return and 53% less likely of having their cancer spread to distant parts of their body, compared with placebo. These reductions in risk with nivolumab were seen in different subgroups of people with a range of characteristics, and regardless of how deep the melanoma had gone into the skin. People taking nivolumab had more side effects than those taking placebo, but most were mild to moderate and manageable. WHAT DO THE RESULTS MEAN?: Results from CheckMate 76K support the benefit of using nivolumab as a treatment option for people with stage 2 melanoma post-surgery.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006490
003      
CZ-PrNML
005      
20240423155320.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/fon-2023-0977 $2 doi
035    __
$a (PubMed)38390818
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kirkwood, John M $u UPMC Hillman Cancer Center, Pittsburgh, PA, USA
245    10
$a Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery / $c JM. Kirkwood, MD. Vecchio, J. Weber, C. Hoeller, JJ. Grob, P. Mohr, C. Loquai, C. Dutriaux, V. Chiarion-Sileni, J. Mackiewicz, P. Rutkowski, P. Arenberger, G. Quereux, TM. Meniawy, PA. Ascierto, AM. Menzies, P. Durani, M. Lobo, F. Campigotto, B. Gastman, GV. Long
520    9_
$a WHAT IS THIS SUMMARY ABOUT?: In this article, we summarize results from the ongoing phase 3 CheckMate 76K clinical study published online in Nature Medicine in October 2023. The study goal was to learn whether nivolumab works as an adjuvant therapy (that is, helps to keep cancer from coming back when it is given after surgery) for stage 2 melanoma (skin cancer) that has not spread to other parts of the body. Nivolumab is an immunotherapy that activates a person's immune system so it can destroy cancer cells. In melanoma, staging describes the severity of the cancer. Melanoma staging ranges from 0 (very thin and confined to the upper layer of the skin) to 4 (spread to distant parts of the body), with earlier stages removed by surgery. The people in this study had stage 2 melanoma that had not spread to the lymph nodes or other organs in the body. HOW WAS THE STUDY DESIGNED?: People 12 years and older with stage 2 melanoma that had not spread and had been removed by surgery were included in CheckMate 76K. People were randomly assigned to receive either nivolumab (526 patients) or placebo (264 patients). A placebo resembles the test medicine but does not contain any active medicines. The researchers assessed whether people who received nivolumab lived longer without their cancer returning and/or spreading to other parts of their bodies (compared with placebo) and if nivolumab was well tolerated. WHAT WERE THE RESULTS?: Researchers found that people who received nivolumab were 58% less likely to have their cancer return and 53% less likely of having their cancer spread to distant parts of their body, compared with placebo. These reductions in risk with nivolumab were seen in different subgroups of people with a range of characteristics, and regardless of how deep the melanoma had gone into the skin. People taking nivolumab had more side effects than those taking placebo, but most were mild to moderate and manageable. WHAT DO THE RESULTS MEAN?: Results from CheckMate 76K support the benefit of using nivolumab as a treatment option for people with stage 2 melanoma post-surgery.
650    _2
$a lidé $7 D006801
650    12
$a melanom $x patologie $7 D008545
650    _2
$a nivolumab $7 D000077594
650    _2
$a ipilimumab $x terapeutické užití $7 D000074324
650    12
$a nádory kůže $x farmakoterapie $x chirurgie $x etiologie $7 D012878
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Vecchio, Michele Del $u Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
700    1_
$a Weber, Jeffrey $u NYU Langone Medical Center, New York, NY, USA
700    1_
$a Hoeller, Christoph $u Medizinische Universität Wien, Vienna, Austria
700    1_
$a Grob, Jean-Jacques $u Hôpital de la Timone, Marseille, France
700    1_
$a Mohr, Peter $u Elbe Kliniken Buxtehude, Buxtehude, Germany
700    1_
$a Loquai, Carmen $u University of Mainz Medical Center, Mainz, Germany
700    1_
$a Dutriaux, Caroline $u Hôpital Saint André, Bordeaux, France
700    1_
$a Chiarion-Sileni, Vanna $u Istituto Oncologico Veneto IRCCS, Padova, Italy
700    1_
$a Mackiewicz, Jacek $u Institute of Oncology, Poznan University of Medical Sciences, Poznan, Poland
700    1_
$a Rutkowski, Piotr $u Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
700    1_
$a Arenberger, Petr $u Charles University Third Faculty of Medicine & University Hospital of Královské Vinohrady, Prague, Czech Republic
700    1_
$a Quereux, Gaelle $u Nantes University Hospital, Nantes, France
700    1_
$a Meniawy, Tarek M $u University of Western Australia & Sir Charles Gairdner Hospital, Perth, WA, Australia
700    1_
$a Ascierto, Paolo A $u Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy
700    1_
$a Menzies, Alexander M $u Melanoma Institute Australia, University of Sydney, & Royal North Shore & Mater Hospitals, Sydney, NSW, Australia
700    1_
$a Durani, Piyush $u Bristol Myers Squibb, Princeton, NJ, USA
700    1_
$a Lobo, Maurice $u Bristol Myers Squibb, Princeton, NJ, USA
700    1_
$a Campigotto, Federico $u Bristol Myers Squibb, Princeton, NJ, USA
700    1_
$a Gastman, Brian $u Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Long, Georgina V $u Melanoma Institute Australia, University of Sydney, & Royal North Shore & Mater Hospitals, Sydney, NSW, Australia
773    0_
$w MED00008687 $t Future oncology $x 1744-8301 $g Roč. 20, č. 15 (2024), s. 959-968
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38390818 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155317 $b ABA008
999    __
$a ok $b bmc $g 2080842 $s 1216257
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 20 $c 15 $d 959-968 $e 20240223 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options